Circulating microRNA-19a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction

Zhong, Jianfeng; He, Yuan; Chen, Wenjiang; Shui, Xiaorong; Chen, Can; Lei, Wei

doi:10.3390/ijms151120355

Cited by 59 publications

(36 citation statements)

References 26 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data extracted from the included, missing, 41–43 and excluded studies, with an appropriate study design but insufficient quality 11,44–65 and with a less reliable study design and insufficient quality, 66–92 are available in Supplementary material online, File 2 .…”

Section: Resultsmentioning

confidence: 99%

Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review

et al. 2016

View full text Add to dashboard Cite

The aim of the present study is to identify microRNAs (miRs) with high potential to be used as biomarkers in plasma and/or serum to clinically diagnose, or provide accurate prognosis for survival in, patients with atherosclerosis, coronary artery disease, and acute coronary syndrome (ACS). A systematic search of published original research yielded a total of 72 studies. After review of the risk of bias of the published studies, according to Cochrane Collaboration and the QUADUAS Group standards, 19 studies were selected. Overall 52 different miRs were reported. In particular, miR-133a/b (5 studies), miR-208a/b (6 studies), and miR-499 (7 studies) were well studied and found to be significant diagnostic and/or prognostic markers across different cardiovascular disease progression stages. miR-1 and miR-145b are potential biomarkers of ACS; miR-1 with higher sensitivity for all acute myocardial infarction (AMI), and miR-145 for STEMI and worse outcome of AMI. But when miRs were studied across different ACS study populations, patients had varying degrees of coronary stenosis, which was identified as an important confounder that limited the ability to quantitatively pool the study results. The identified miRs were found to regulate endothelial function and angiogenesis (miR-1, miR-133), vascular smooth muscle cell differentiation (miR-133, miR-145), communication between vascular smooth muscle and endothelial cell to stabilize plaques (miR-145), apoptosis (miR-1, miR-133, miR-499), cardiac myocyte differentiation (miR-1, miR-133, miR-145, miR-208, miR-499), and to repress cardiac hypertrophy (miR-133). Their role in these processes may be explained by regulation of shared RNA targets such as cyclin-dependent kinase inhibitor 1A (or p21), ETS proto-oncogene 1, fascin actin-bundling protein 1, hyperpolarization-activated cyclic nucleotide-gated potassium channel 4, insulin-like growth factor 1 receptor LIM and SH3 protein 1, purine nucleoside phosphorylase, and transgelin 2. These mechanistic data further support the clinical relevance of the identified miRs. miR-1, miR-133a/b, miR-145, miR-208a/b, and miR-499(a) in plasma and/or serum show some potential for diagnosis of cardiovascular disease. However, biased selection of miRs in most studies and unexplained contrasting results are major limitations of current miR research. Inconsistencies need to be addressed in order to definitively identify clinically useful miRs. Therefore, this paper presents important aspects to improve future miR research, including unbiased selection of miRs, standardization/normalization of reference miRs, adjustment for patient comorbidities and medication, and robust protocols of data-sharing plans that could prevent selective publication and selective reporting of miR research outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The discrepancy among the results can be partly explained by the fact that each group used a different blood fraction (plasma or serum) while the two groups that determined the miR-1 in plasma samples used a different type of anticoagulant. Specifically, Liu et al [73] used collection tubes containing EDTA while in the study of Zhong et al [74] tubes containing citrate were used from plasma isolation. In the third study, Li at el.…”

Section: Effect Of Sample Selection and Processing In Evaluating The mentioning

confidence: 99%

Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases

Felekkis

Papaneophytou

2020

IJMS

View full text Add to dashboard Cite

Micro-RNAs (miRNAs) play a pivotal role in the development and physiology of the cardiovascular system while they have been associated with multiple cardiovascular diseases (CVDs). Several cardiac miRNAs are detectable in circulation (circulating miRNAs; c-miRNAs) and are emerging as diagnostic and therapeutic biomarkers for CVDs. c-miRNAs exhibit numerous essential characteristics of biomarkers while they are extremely stable in circulation, their expression is tissue-/disease-specific, and they can be easily detected using sequence-specific amplification methods. These features of c-miRNAs are helpful in the development of non-invasive assays to monitor the progress of CVDs. Despite significant progress in the detection of c-miRNAs in serum and plasma, there are many contradictory publications on the alterations of cardiac c-miRNAs concentration in circulation. The aim of this review is to examine the pre-analytical and analytical factors affecting the quantification of c-miRNAs and provide general guidelines to increase the accuracy of the diagnostic tests in order to improve future research on cardiac c-miRNAs.

show abstract

“…Hence, miRNAs may become novel regulators involved in the diagnosis of psoriasis. Peripheral blood was attractive for biomarker discovery . miR‐223 and miR‐143 were found to significantly upregulate in the PBMCs from patients with psoriasis, and these miRNA significantly correlated with PASI score.…”

Section: Mirna As Potential Biomarkers In Psoriasismentioning

confidence: 99%

Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers

Liu

Han

et al. 2017

Experimental Dermatology

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNA molecules, which function in RNA silencing and post-transcriptional regulation of gene expression. Psoriasis is an inflammatory skin disease characterized by the dysfunction of keratinocytes, with the immune dysregulation. We reviewed the recent studies on the roles of miRNAs in psoriasis and showed that miRNAs play key roles in psoriasis, including the regulation of hyperproliferation, cytokine and chemokine production in keratinocyte, as well as mediating immune dysfunction in psoriasis. Furthermore, miRNAs, particularly, circulating miRNAs may serve as novel biomarkers for diagnosis, monitoring therapy response and reflecting the disease severity. Thus, targeting specific miRNAs may be used to develop new therapeutic methods for psoriasis.

show abstract

Circulating microRNA-19a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction

Cited by 59 publications

References 26 publications

Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review

Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review

Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases

Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers

Contact Info

Product

Resources

About